SynthesisThe journal of headache and pain2026
Rimegepant for the acute treatment of migraine: a systematic review and meta-analysis.
Synthesis in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the efficacy and tolerability of a single 75 mg oral dose of rimegepant compared with placebo for the acute treatment of migraine attacks in adults.
methodsA systematic review and meta-analysis were conducted in accordance with PRISMA guidelines, with the protocol prospectively registered in PROSPERO (Identifier: CRD420251042015). Comprehensive searches of CENTRAL, ClinicalTrials.gov, EMBASE, EUCTR, PubMed, and WHO ICTRP were performed from database inception to December 2025, without language restrictions. Supplementary sources were also reviewed, including regulatory and sponsor materials such as FDA and EMA submissions and entries in the Pfizer and Biohaven clinical trial registries. Eligible studies were double-blind randomized controlled trials enrolling adults (≥ 18 years) with migraine (with or without aura) who received a single 75 mg oral dose of rimegepant compared with placebo for the acute treatment of migraine attacks. The co-primary outcomes were pain freedom at 2 h post-dose and sustained pain freedom from 2 to 24 h post-dose. Tolerability outcomes included all non-serious adverse events (AEs) following dosing, whereas safety outcomes comprised serious adverse events. Risk of bias was evaluated using the Cochrane RoB 2 tool, and certainty of evidence was assessed using the GRADE framework. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model, and heterogeneity was quantified using the I² and τ² statistics.
resultsSeven double-blind RCTs (one phase II, five phase III, one phase IV) comprising 6,734 participants met the inclusion criteria. Two hours post-dose, 19.8% of participants receiving rimegepant and 10.7% receiving placebo achieved pain freedom (RR, 1.93; 95% CI, 1.51-2.47; P < 0.001; NNT = 10). Sustained pain freedom from 2 to 24 h was achieved by 14.2% of those receiving rimegepant, compared with 6.3% receiving placebo (RR, 2.39; 95% CI, 1.75-3.27; P < 0.001; NNT = 11). AEs occurred in 14.3% of rimegepant-treated and 12.7% of placebo-treated participants (RR, 1.14; 95% CI, 1.00-1.30; P = 0.056; NNH = 55). Risk of bias was judged as low across the included trials.
conclusionsRimegepant 75 mg provides modest yet clinically meaningful efficacy with favorable short-term tolerability for the acute treatment of migraine attacks. These findings support its use as an effective treatment option for adults with inadequate response, contraindications, or intolerance to first- or second-line therapies. CLINICAL TRIALS NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.